- Odell Beckham Jr. first
noticed flakes throughout his iconic beard and hairline in his 20s;
today, for the first time he is sharing his experience with ZORYVE®
(roflumilast) topical foam, 0.3%, to help others learn more about
this chronic inflammatory skin condition
- ZORYVE foam is a once-daily, steroid-free, topical for
seborrheic dermatitis uniquely formulated for use anywhere on the
body, including hair-bearing areas
- Seborrheic dermatitis impacts more than 10 million Americans
and is the third most common skin condition affecting
Blacks
WESTLAKE
VILLAGE, Calif., Feb. 4, 2025
/PRNewswire/ -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT),
a commercial-stage biopharmaceutical company focused on developing
meaningful innovations in immuno-dermatology, today announced a
partnership with the iconic professional football player,
Odell Beckham Jr. ("OBJ"), to help
raise awareness of seborrheic dermatitis ("seb derm") a common,
chronic, recurrent inflammatory skin disease that can cause
flaking, redness, itching, and discoloration of the skin.
Experience the full interactive Multichannel News Release here:
https://www.multivu.com/arcutis/9314051-en-odell-beckham-jr-arcutis-clear-win-for-your-skin-seborrheic-dermatitis-campaign
"My seborrheic dermatitis started to bother me in my 20s when I
noticed white flaky skin throughout my beard and at my hairline
accompanied by a deep, burning itchy sensation that was extremely
uncomfortable," said Odell Beckham
Jr., a father, professional football player, and ZORYVE
spokesperson. "After trying to figure out the cause for several
years, I finally visited my dermatologist who diagnosed me with seb
derm and prescribed ZORYVE foam, which works really well for me.
Now I want to help others understand the condition, find a
treatment option that works for them, and get a clear win for their
skin."
Seborrheic dermatitis is a common, chronic, recurrent
inflammatory skin disease that affects approximately 10 million
Americans and occurs most often on areas of the body with
oil-producing (sebaceous) glands, including the scalp, face
(especially on and around the nose, eyebrows, and eyelids), ears,
upper chest, and back. The path to diagnosis can be challenging,
often leading to misdiagnosis, which can delay treatment.
"Seborrheic dermatitis is a common condition that I see
frequently in my practice, particularly among Black patients," said
Dr. Karan Lal, DO, MS, FAAD,
double-board certified dermatologist. "Seb derm is often
misunderstood or misdiagnosed, and it can present differently in
darker skin tones appearing more purple instead of red, so it is
crucial to have a proper diagnosis. The key to managing seborrheic
dermatitis effectively is finding the right treatment that works
for each individual. ZORYVE is a unique treatment option because it
is a steroid-free topical foam that can be used anywhere on the
body, including the scalp, face and beard, to help clear skin and
reduce itch."
ZORYVE foam, 0.3%, is indicated for the treatment of seborrheic
dermatitis in adult and pediatric patients 9 years of age and
older. ZORYVE foam provides rapid disease clearance and significant
reduction in itch, with nearly 80% of the 458 individuals using
ZORYVE achieving clear or almost clear skin at Week 8 in two
clinical trials, compared to 53% of the 225 individuals who used a
vehicle (a foam not containing the active ingredient). In addition,
63% of the 206 individuals using ZORYVE had significant itch relief
at Week 8, compared to 41% of the 98 people using a vehicle, in one
of the clinical trials. ZORYVE is a once-daily steroid-free foam
and was the first drug approved for seborrheic dermatitis with a
new mechanism of action in over two decades.
"We know that beyond the appearance and irritation of physical
symptoms, for many people seborrheic dermatitis can cause a
decrease in quality of life and may affect emotional well-being,
self-esteem, and day-to-day life," said Frank Watanabe, president and chief executive
officer of Arcutis. "That's why we're excited to team up with OBJ
to encourage people who may be suffering from this condition to
speak with their dermatology specialist to see if ZORYVE foam is
right for them."
Odell Beckham Jr. adds, "Seb derm
is such a common condition but like me, many people may have a hard
time trying to figure out what it is and what can be done about it.
I want to inspire people not to be embarrassed or discouraged about
their condition and instead be empowered to find a dermatologist
and work together to find a treatment that works for them."
ZORYVE foam is safe and well tolerated. The most common side
effects are common cold, nausea, and headache. For more information
on ZORYVE foam including full prescribing information, please
visit ZORYVE.com.
About ZORYVE®
ZORYVE (roflumilast) topical foam, 0.3%, is indicated for treatment
of seborrheic dermatitis in adult and pediatric patients 9 years of
age and older. Another formulation of ZORYVE, roflumilast cream,
0.3%, is approved by the FDA for the topical treatment of plaque
psoriasis in individuals 6 years of age and older. ZORYVE
roflumilast cream, 0.15%, is approved by the FDA for the topical
treatment of mild to moderate atopic dermatitis in patients 6 years
of age and older. In 2024, ZORYVE cream, 0.15%, was awarded
Glamour's Beauty and Wellness award. Both ZORYVE foam and cream are
topical formulations of roflumilast, a highly potent and selective
phosphodiesterase-4 (PDE4) inhibitor. PDE4 is an intracellular
enzyme that increases the production of pro-inflammatory mediators
and decreases production of anti-inflammatory mediators. It is an
established target in dermatology.
INDICATIONS
ZORYVE foam, 0.3%, is indicated for the treatment of seborrheic
dermatitis in adult and pediatric patients 9 years of age and
older.
ZORYVE cream, 0.3%, is indicated for topical treatment of plaque
psoriasis, including intertriginous areas, in adult and pediatric
patients 6 years of age and older.
ZORYVE cream, 0.15%, is indicated for topical treatment of mild
to moderate atopic dermatitis in adult and pediatric patients 6
years of age and older.
IMPORTANT SAFETY INFORMATION
ZORYVE is contraindicated in patients with moderate to severe
liver impairment (Child-Pugh B or C).
Flammability: The propellants in ZORYVE foam are
flammable. Avoid fire, flame, and smoking during and immediately
following application.
The most common adverse reactions (≥1%) for ZORYVE foam 0.3% for
seborrheic dermatitis include nasopharyngitis (1.5%), nausea
(1.3%), and headache (1.1%).
The most common adverse reactions (≥1%) for ZORYVE cream 0.3%
for plaque psoriasis include diarrhea (3.1%), headache (2.4%),
insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper
respiratory tract infection (1.0%), and urinary tract infection
(1.0%).
The most common adverse reactions (≥1%) for ZORYVE cream 0.15%
for atopic dermatitis include headache (2.9%), nausea (1.9%),
application site pain (1.5%), diarrhea (1.5%), and vomiting
(1.5%).
Please see full Prescribing Information for ZORYVE
foam and full Prescribing Information for ZORYVE
cream.
ZORYVE is for topical use only and not for ophthalmic, oral, or
intervaginal use.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq:
ARQT) is a commercial-stage medical dermatology company that
champions meaningful innovation to address the urgent needs of
individuals living with immune-mediated dermatological diseases and
conditions. With a commitment to solving the most persistent
patient challenges in dermatology, Arcutis has a growing portfolio
including three FDA approved products that harness our unique
dermatology development platform coupled with our dermatology
expertise to build differentiated therapies against biologically
validated targets. Arcutis' dermatology development platform
includes a robust pipeline with multiple clinical programs for a
range of inflammatory dermatological conditions including scalp and
body psoriasis, atopic dermatitis, and alopecia areata. For more
information, visit www.arcutis.com or follow Arcutis
on LinkedIn, Facebook, Instagram, and X.
Forward-Looking Statements
Arcutis cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. These statements are based on the
Company's current beliefs and expectations. Such forward-looking
statements include, but are not limited to, statements regarding
the potential of ZORYVE foam to simplify disease management for
care of seborrheic dermatitis; or the potential of real-world use
results of ZORYVE foam on individual patients. These statements are
subject to substantial known and unknown risks, uncertainties and
other factors that may cause our actual results, levels of
activity, performance, or achievements to be materially different
from the information expressed or implied by these forward-looking
statements. Risks and uncertainties that may cause our actual
results to differ include risks inherent in our business,
reimbursement and access to our products, the impact of competition
and other important factors discussed in the "Risk Factors" section
of our Form 10-K filed with the U.S. Securities and Exchange
Commission (SEC) on February 27,
2024, as well as any subsequent filings with the SEC. You
should not place undue reliance on any forward-looking statements
in this press release. We undertake no obligation to revise or
update information herein to reflect events or circumstances in the
future, even if new information becomes available. All
forward-looking statements are qualified in their entirety by this
cautionary statement, which is made under the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995.
View original
content:https://www.prnewswire.com/news-releases/odell-beckham-jr-and-arcutis-tackle-seborrheic-dermatitis-in-a-clear-win-for-your-skin-302366903.html
SOURCE Arcutis Biotherapeutics, Inc.